Life Sciences-Related Business and Commercialization of Microfluidic Chips
First written in FY2017. 8 of 10 entries say "Advanced", first in FY2020. Latest entry: 2026-08-06.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「In the life sciences business, net sales increased 12.4% year on year to ¥538 million, as orders for bio-related products remained solid. Segment profit increased 11.8% year on year to ¥129 million, as the rise in raw material, labor, and other costs was absorbed through productivity improvements, rationalization, and reflecting costs in selling prices, in addition to higher sales.」
In the life sciences business, orders for bio-related products remained solid, with net sales up 12.4% year on year and segment profit up 11.8%. - FY2025AdvancedAnnual report
「In addition, for the antimicrobial resistance testing chip in the field of bacterial testing, we will seek insurance coverage in FY2027 and aim to expand its full-scale deployment in medical settings and grow the business.」
In the life sciences business, the company has set the time-bound target of obtaining insurance coverage for its antimicrobial resistance testing chip in FY2027 and aims to deploy it in medical settings. - FY2025-H1AdvancedAnnual report
「In the life sciences business, net sales increased 20.5% year on year to ¥478 million, reflecting strong orders. Segment profit increased 39.2% year on year to ¥116 million.」
In the life sciences business, strong orders drove a 20.5% year-on-year increase in net sales and a 39.2% increase in segment profit, demonstrating progress in business expansion through the results. - FY2024AdvancedAnnual report
「We have also launched cell cryopreservation solutions, cell freezing bags, and cell-dispersing enzyme solutions used in regenerative medicine and cell processing, and are advancing the development of higher-value-added system bags and high-performance media for regenerative medicine.」
In the life sciences-related business, the company has launched cell cryopreservation solutions, cell freezing bags, and cell-dispersing enzyme solutions, and is expanding product development into system bags and high-performance media. - FY2023AdvancedAnnual report
「In the life sciences business, we began selling the rapid bacterial testing kit RaST-TAS β-lactamase Screening Reagent Kit through Sugiyama Gen Co., Ltd. in June 2023. We have also launched cell cryopreservation solutions, cell freezing bags, cell-dispersing enzyme solutions, and other products used in regenerative medicine and cell processing, which are being evaluated by universities, companies, clinics, and other organizations.」
In the life sciences business, the company reports the launch of a rapid bacterial testing kit, the commercialization of cell cryopreservation-related products, and evaluations by universities, companies, and clinics, indicating progress in commercialization and sales expansion. - FY2022AdvancedAnnual report
「The cosmetics ingredients developed in 2020, namely human adipose-derived stem cell conditioned medium (product name: Phicello ファイセロ) and human adipose-derived stromal cell exosomes (product name: Phisome ファイソーム), are seeing wider adoption. In 2021, a cosmetics ingredient produced using dermal papilla cells, human hair follicle cell conditioned medium (product name: Phicello mou ファイセロ モウ), was adopted for use in hair-growth products.」
In the life sciences-related business, the company reports wider adoption of existing products and adoption of a new product in hair-growth products, indicating progress in commercialization and sales expansion. - FY2020AdvancedAnnual report
「We newly began selling our original mesenchymal stem cell culture medium to domestic and overseas research facilities specializing in immunology and cosmetics.」
In the life sciences-related business, the company began selling mesenchymal stem cell culture medium and also began providing samples and selling prototypes of SphereRing. - FY2017First statedAnnual report
「With the goal of expanding the life sciences-related business, we established a new research center to commercialize microfluidic chips, a new product for the company.」
The company describes the establishment of a research center to commercialize microfluidic chips, with the goal of expanding its life sciences-related business.